Smart insulin pens market seen nearly doubling by 2033

Persistence Market Research projects the global smart insulin pens market will rise from $1.0 billion in 2026 to $1.9 billion by 2033, driven by demand for connected diabetes tools, better adherence and wider use in hospitals and specialty clinics. North America leads today, while Europe and Asia Pacific add growth as digital healthcare adoption expands.

Why it matters: - Smart insulin pens are gaining traction because they can track doses, send reminders and connect to mobile apps. - The devices are designed to improve insulin adherence and reduce missed or incorrect doses, which can affect diabetes outcomes. - Rising diabetes prevalence and the shift toward digital health are expanding demand across developed and emerging markets.

What happened: - Persistence Market Research estimated the global smart insulin pens market at $1.0 billion in 2026. - The firm projects the market will reach $1.9 billion by 2033. - The forecast implies a 9.8% compound annual growth rate from 2026 to 2033. - The report was released July 16, 2026. - More information is available through the report sample page.

The details: - Reusable smart insulin pens hold the leading product share because of long-term cost efficiency and stronger digital features. - Reusable devices offer dose recording, connectivity and compatibility with digital health applications. - Disposable smart insulin pens remain a separate market segment. - Hospitals and specialty diabetes clinics are the main end users. - Home healthcare is also growing as patients look for remote monitoring and easier self-management. - North America leads the market because of advanced healthcare infrastructure, widespread digital health use and high diabetes awareness. - Europe is a meaningful market supported by healthcare digitalization and rising patient awareness. - Asia Pacific is emerging as a faster-growing region because of expanding healthcare infrastructure, higher diabetes prevalence and broader access to connected devices.

Between the lines: - The market is being pulled by a broader move toward personalized diabetes care and connected medical devices. - Higher device costs remain a brake on adoption, especially in price-sensitive health systems. - Limited awareness and training in developing regions can slow uptake of connected insulin delivery tools. - The competitive field includes Novo Nordisk A/S, Medtronic plc, Eli Lilly and Company, Sanofi, Companion Medical, Emperra GmbH and Digital Medics Pty Ltd.

What's next: - Manufacturers are expected to keep investing in mobile connectivity, dose tracking and patient monitoring features. - Integration with digital health platforms and remote patient monitoring systems should support broader use. - Growing healthcare investment in emerging markets could open additional demand as access and awareness improve. - Report customization and full purchase options are available for buyers.

The bottom line: - Smart insulin pens are moving from niche devices toward a mainstream diabetes management tool, with connected features and better adherence driving the next phase of growth.